Correction to: Thymine DNA glycosylase as a novel target for melanoma

Affiliations

• ¹ Cancer Epigenetics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
• ² Department of Medical Biotechnologies, Universita' degli Studi di Siena, Siena, Italy.
• ³ Institut Curie, PSL Research University, INSERM U1021, Normal and Pathological Development of Melanocytes, 91405, Orsay, France.
• ⁴ Cancer Biology Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
• ⁵ Fels Institute for Cancer and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, 19140, USA.
• ⁶ Department of Biostatistics, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
• ⁷ Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA.
• ⁸ Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA.
• ⁹ Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, 67404, Illkirch, France.
• ¹⁰ Equipe Labellisée Ligue Contre le Cancer, Orsay, France.
• ¹¹ University Paris-Sud, University Paris-Saclay, CNRS UMR3347, Orsay, France.
• ¹² Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA.
• ¹³ Cancer Epigenetics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA. Alfonso.Bellacosa@fccc.edu.